Objectives: We investigate the combination of transcatheter aortic-valve implantation (TAVI) and a novel concept of stem cell-based, tissue-engineered heart-valves (TEHV) comprising minimally-invasive techniques for both, cell-harvest and valve-delivery.
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Introduction
Valvular heart-disease (VHD) represents a major cause of mortality around the globe [1, 2] . The therapy options for affected patients are currently undergoing rapid changes and in addition to conventional, surgical valve replacement representing the standard of care since several decades, transcatheter techniques have entered the clinicalroutine representing an efficient alternative for the treatment of elderly high-risk patients [3] [4] [5] [6] . Given sufficient long-term safety, it can be predicted that these minimally-invasive techniques may have a major impact on the treatment strategy of patients with VHD and will further be expanded to a broader and younger patient population.
However, despite this rapid technical progress, the currently available prostheses for transcatheter-approaches are still bio-prosthetic associated with the known disadvantages comprising progressive calcification and degeneration. Furthermore, recent evidence suggests even accelerated degeneration resulting from structuraldamage due to the crimping-procedures [7] . Therefore, so far, the clinical indication for transcatheter valves is limited primarily to the elderly, high-risk patients [3, 5, 6] .
A living heart-valve prosthesis created by tissue-engineering technologies with regeneration and repair capacities would overcome such limitations [8] . A clinically relevant heart-valve tissue-engineering concept (HVTE) would ideally comprise minimally-invasive techniques for both, cell-harvest and valve-implantation. We have demonstrated the technical feasibility of combining the concept of HVTE and transapical delivery into the pulmonary-position of adult sheep [9] . Thereafter, in a recent proof-of-concept study we introduced a novel and clinically highly relevant concept of in-vivo implantation of autologous bone-marrow mononuclear cell (BMMC)-derived tissue-engineered heart-valves (TEHV) in a primate model [10] . Based on previously described techniques that are currently entering the clinical-arena following recent FDA The aim of this study was to assess the principal feasibility of implanting stem cellbased, tissue-engineered heart-valves (TEHV) into the aortic-valve position using a transcatheter, one-step interventional approach. Beside the technical feasibility of the deployment of a TEHV in the aortic-position, the major endpoints of this study were the assessment of the valve-functionality and initial tissue-remodelling phenomena of TEHV in the aortic-position.
Materials & Methods
Experimentation approval
All animals received humane care in compliance with the "Principles of Laboratory Animal-Care" as well as with the ''Guide for the care and use of laboratory animals" 
Study Design
The study aim was to assess the principal feasibility of implanting stem cell-based, tissue-engineered heart-valves (TEHV) into the orthotopic, aortic-valve position using a transcatheter, one-step interventional approach ( figure 1, supplementary figure 1 ). The study animals (adult sheep/n=12) were divided into three groups: Group A (acute group/n=4), Group B (subacute group/n=5) and Group C (chronic group/n=3).
In the first set of experiments, the animals of group A (n=4) were used in an acute fashion (up to 4hours) to establish the technical-feasibility of transapical TEHV implantation into the orthotopic, aortic-position with a specific focus on technical aspects such as device-insertion, stepwise delivery and optimal positioning considering the anatomical condition of the aortic-annulus, the aortic-root and the coronaries. In order to assess TEHV stability and functionality as well as early tissue-reaction and remodeling in the systemic-pressure system, the other animals were planned to be either followed up for 48hours (subacute group/n=4) or up to 1week (chronic group/n=3).
Scaffold Fabrication
Trileaflet heart-valve scaffolds were fabricated as previously described [10, 18] (see supplementary file 1).
Isolation, Characterization and Differentiation of ovine Bone-Marrow Mononuclear Cells (BMMCs)
See supplementary file 1 and supplementary figure 1.
Seeding of ovine BMMCs
Fibrin was used as a cell-carrier to seed BMMCs onto the stented heart-valve scaffolds (1.73±0.47 x10 6 cells/cm 2 valve-leaflets) (Sigma Chemical /USA), before the stented TEHV was loaded into the delivery-device by crimping the outer diameter from 25mm down to 8mm (see supplementary file 1).
Preoperative Assessment, Planning and Sizing
Prior to implantation all sheep underwent trans-thoracic echocardiography (TTE) in order to adapt the ideal stent-size to each animal. Before starting the implantationprocedure the following parameters were measured by intra-operative angiography to re-confirm the ideal stent-size: diameters of the Aortic-Annulus (AA), Sinus-Portion (SP), the Sinus-Tubular Junction (STJ) and the Brachiocephalic-Trunc (BCT) as well as the distance to the BCT and the height of the SP (table 1) . Animals with an annulus between 22-23mm received a 25mm stented TEHV (n=8), while animals with an annulus of 24-25mm received a 27mm stented TEHV (n=4).
Transcatheter Implantation of stem cell-based TEHV into the aortic-valve position
TEHV were transapically delivered into the aortic-valve position via a mini-sternotomy (figure 1). The valves were crimped and loaded onto a custom-made, guide-wired inducing system (OD=8mm). The apex of the left-ventricle was punctured after 5/0
Prolene pledged, purse-string sutures were placed. TEHV were delivered into the aortic-valve position under fluoroscopic-control (OECW 9900 Elite GE, Fairfield/USA).
After the stepwise opening and positioning of the distal part of the stent in the aorticroot under fluoroscopic-control, the proximal part of the stent was instantly delivered.
The appropriate placement and functionality of the implanted valve was confirmed by contrast-angiography, before the device was carefully removed and the purse-string sutures were tightened.
Assessment of stent positioning and TEHV-functionality
Stent positioning was controlled using angiography and computed-tomography (CT, Siemens, Munich/Germany). In-vivo functionality was evaluated using intra-operative, epicardial 2D-and 3D-echocardiography ((Philips Healthcare iE33W xMATRIX Ultrasound/Netherlands). Trans-thoracic echocardiography (TTE) was serially performed until to the sacrifice of the animal. Three-dimensional CT reconstruction and volume rendering were performed using the OsiriX Image Processing Software (OsiriX Mac OSX; Version 3.8.1).
Postoperative Care & Follow-Up
The animals were sacrificed applying potassium euthanization and exsanguination.
Thereafter the hearts were harvested and the TEHV were excised for in-vitro analysis.
Anticoagulation was maintained for until sacrifice.
Histology & Scanning Electron Microscopy
Tissue samples of the explanted TEHV were analyzed qualitatively via histology and Scanning Electron Microscopy (see supplementary file 1).
Quantitative Explant Tissue Analysis
Explanted TEHV were lyophilized and analyzed by biochemical assays for total DNA and Glycosaminoglycans (GAG) content (see supplementary file 1).
Statistical Analysis
Quantitative data are presented as mean±standard-deviation (SPSS 17.0, IBM, Somers/USA).
Results
Cell Isolation, Characterization and Preparation of TEHV
Ovine BMMCs were evaluated by flow cytometric analysis. Surface-marker expression of CD29 (mean±SD, 59.0%±7.0%) and CD44 (61.0%±16.7%) was detected. Less than 4% of the cells were positive for CD31 (3.7%±1.7%), CD34 (3.7%±1.0%) and CD166 
Trans-catheter aortic-valve implantation of stem cell-based TEHV
Delivery, positioning and intra-operative complications
Transcatheter aortic-valve implantation of stem cell-based TEHV could be performed Consecutively, it further migrated into the left-ventricle and the animal was sacrificed due to beginning acute left heart-failure. Another animal of group B had to be terminated due to severe valvular-dysfunction displaying severe central-regurgitation immediately after implantation.
The mean duration from cell-harvest until TEHV-loading was 64±8 minutes and the mean crimping time until trans-apical delivery, was 12±6 minutes. The mean duration of the entire procedure, starting from cell-harvest until TEHV implantation, was 109±14 minutes (table 2) .
Performance of TEHV and acute echocardiography findings
Acute TEHV functionality and mobility was controlled via fluoroscopy ( figure 3G ) and epicardial echocardiography (EE). Except the two terminated animals, in all other study animals (n=10) a sufficient opening and closing pattern of the TEHV was observed and the loading-pressure of the systemic-circulation was well tolerated (figure 5A and B, supplementary trailer 2A). TEHV functionality was confirmed in the 2D-color mode and the 3D-mode demonstrating good leaflet mobility and co-aptation (figure 5C-G, supplementary trailer 2B-C). The mean trans-valvular gradient was 8.4±2.0mmHg and the mean effective orifice-area (EOA) was 1.4±0.1cm² (table 2) . Only one animal displayed a mild mitral-regurgitation and none of the animals showed central aorticregurgitation. In contrast, in 40% of the animals, an at least mild paravalvular-leakage was present (table 2) which was rather related to the stent-shape and design, but not to the TEHV itself.
Early postoperative period, complications and follow-up
Except the two terminated animals, all other animals of group B (3/5) and group C (3/3) tolerated the procedure very well without any hemodynamic compromise and could be waken up immediately. Despite of an uneventful TEHV-delivery and an excellent TEHV functionality without any signs of regurgitation or paravalvular-leakage, one animal of group C died due to acute stent-dislocation. All other study animals were monitored regularly and received regular doses of aspirine until the planned harvest.
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The two remaining animals of group C (chronic group; planned to be followed-up for 1week) displayed a sufficient TEHV in-vivo functionality on trans-thoracic and transesophageal echocardiography (TTE/TEE) at 1week with a mean transvalvular gradient of 8.0±1.7mmHg and a mean EOA of 1.5±0.1cm².
Therefore, it was decided to harvest only one animal and to keep the last remaining chronic animal for an additional week to gain further insight into the early remodeling process. The remaining animal was clinically followed-up on a daily basis and the prefinal TTE-control on day10 before the planned harvest displayed sufficient TEHVperformance. While preparing for the final-assessment and harvest, the animal suddenly decompensated hours before the planned sacrifice at day14 due to a sudden stent-dislocation.
Explant Macroscopy
Except the animal which had to be terminated due to sudden valve-dysfunction, all other TEHV (n=11) displayed intact leaflet-structures with well defined cusps and sufficient co-aptation, without signs of thrombus-formation, thickening, shrinking or structural-damage ( figure 6A and B) . The TEHV harvested at 1 and 2weeks after implantation displayed to be well integrated into the surrounding tissue by complete tissue covering of the stent-frame ( figure 6C ). The TEHV explanted at 2weeks showed tissue-formation and co-aptation in two fully intact leaflets. The third leaflet (noncoronary) displayed a thin fissure which we assume was however most likely related to the harmful explantation procedure as the stent was completely entrapped in the mitralvalve and adequate tri-leaflet TEHV-functionality was confirmed on TTE 3days before.
Explant Microscopy
After explantation, harvested tissues were analyzed using scanning electron microscopy, histology, and extracellular-matrix analysis (ECM). In SEM, acute TEHV explants revealed a surface with fibrin-reaction characterized by thrombocyte-aggregation as well as leucocyte-attachment (supplementary figure 2) . This was also confirmed in histology, where acute explants showed clear cellular-infiltrates and fibrinformation in H&E staining ( figure 7A and B) . Interestingly, this cellularity only slightly increased in the tissues of the 24hour explants, while all later explants stagesincluding the 1week and the 2week explants tissues-showed clearly increased cellularity ( figure 7C-F) . This observation was also supported by the ECM, which showed increasing DNA and GAG values in the TEHV with increasing time in-vivo (supplementary figure 3A and B) .
Discussion
Transcatheter aortic-valve implantation (TAVI) has been recently implemented into the clinical routine as an attractive alternative for conventional aortic-valve replacement and is expected to have a major impact on the management of VHD [3] [4] [5] [6] . Although these techniques are currently primarily applied to the elderly, high-risk patients [3, 5] , the extension of indication also for younger patient is awaited for the near future.
However, despite the tremendous potential of transcatheter techniques, the currently used valvular prostheses for these approaches are bio-prosthetic and all major disadvantages apply including progressive calcification and functional degeneration [10, [20] [21] [22] .
The concept of tissue engineered heart valves (TEHV) has been repeatedly suggested as a potential solution to overcome the limitations of currently used bioprostheses [20, 23] . In this study and for the first time, we demonstrate the feasibility of this one-step procedure comprising minimally-invasive cell-harvest and transapical delivery for the aortic-valve position successfully replacing aortic-valves in an ovine model. By help of an improved catheter-system allowing for orthotopic, aortic-valve implantation, we were able to further develop and adapt this novel, clinically, highly-relevant one-step procedure for the high-pressure circulation. Our data indicate that BMMC-based TEHV can be successfully implanted into the aortic-position exhibiting competent valvefunctionality and leaflet co-aptation sufficiently withstanding the systemic-pressure load, while any signs of valvular-rupture, tear or structural-damage were absent.
Importantly, this study elucidates that the TEHV fully accepted the systemic-pressure responding with a high degree of early cellularization indicative for an active and extensive tissue-formation and remodeling-process. As previously described, sufficient hemodynamic loading appears to play a key role in tissue-remodeling and formation and is a well established mechanism [24] . The histological findings of this study are supported by the interesting observation in our recent study that elucidated the crucial impact of sufficient hemodynamic loading on functional tissue-remodeling in a nonhuman primate model. In contrast to orthotopically delivered TEHV fully excluding the native leaflets, TEHV that were implanted into the supra-valvular position -not excluding the native leaflets and thereby being fully unloaded-lacked any leafletstructure, being indicative for complete absence of tissue-formation as well as BMMC- Importantly, they also showed that the seeded BMMCs were no longer detectable within a few days after implantation suggesting that the scaffolds were initially repopulated by mouse monocytes by a MCP-1 mediated process [14] . In line with that, the recent study of Hibino confirmed the early absence of seeded BMMCs declining to below 1% after two weeks indicating that the bone-marrow does not represent the significant source of EC or SMC that comprise the newly formed vessel. In contrast, the adjacent vessel wall appeared to be the primary source of these cells forming the major part of the neo-tissue. The authors concluded that tissue-engineered constructs functions by mobilizing the body's innate healing capabilities to "regenerate" neo-tissue from pre-existing committed tissue-cells [25] . The mechanism of a BMMC-mediated chemo-attractive process appears to be confirmed in the present study indicating an early and extensive remodeling process primarily characterized by an early monocyticinfiltration that may even be accelerated due to the systemic pressure-loading.
Another interesting observation in this study was the fact, that macroscopically the TEHV did not display any sign of thickening or shrinking when compared to the previous reports in sheep [9, 19] or primates [10] that presented with functional, but shortened leaflets limiting an optimal co-aptation area. A potential reason may be reflected in the fact, that this study was the first trial performed in the high-pressure circulation while all other studies have been performed in the low-pressure pulmonary circulation [9, 10, 19] . Although highly speculative, the high-pressure environment may play a key role in this regard and may prevent the TEHV from shrinking and thickening.
Consecutive studies will be mandatory to further elucidate the important key-issue of shrinking and to determine the role of pressure in this regard.
Limitations
Based on this proof-of-concept study demonstrating the principal feasibility of transcatheter aortic-valve replacement using BMMC-based valves in a one-step procedure, long-term studies are mandatory to further assess the fate and the underlying remodeling mechanisms of such TEHV. Secondly, the role of the seeded BMMCs and the associated multi-factorial, chemo-attractive remodeling process needs to be systematically evaluated to define quality-criteria of tissue-formation representing a key prerequisite for a safe translation into the clinical-setting. Finally, additional effort is needed to improve the stent-design to further minimize the principle problem of paravalvular-leakage and stent-dislocation that is associated with current transcatheterapproaches and as it was also encountered in the present study.
Conclusions
Considering the tremendous clinical potential of a BMMC-based tissue-engineering approach that has already received FDA approval for clinical application in the setting of tissue engineered vascular grafts and is expected to have an even vaster impact with regards to tissue-engineered heart-valves [11], our study provides the first evidence to facilitate this concept for the successful replacement of aortic-valves using a minimally-invasive trans-catheter approach. Its long-term durability proven, and taking into account the so called ``Ten commandments`` of the heart-valve pioneer Dr.
D.E. Harken [27] defining an optimal heart-valve prosthesis and thereby characterizing a prosthesis with native valve attributes, such tissue-engineered heart-valves may represent the next generation of heart-valves overcoming the limitations of currently used bioprosthetic valves. 
Seeding of ovine BMMCs
Fibrin was used as a cell carrier to seed BMMCs onto the stented heart valve scaffolds (1.73 ± 0.47 x 10 6 cells/cm 2 valve leaflets) (Sigma Chemical Co., USA). Thereafter, the TEHV were placed into vented 50 mL tubes for 10 minutes to allow the fibrin-thrombin solution to clot adequately ( figure 2D) . Next, the TEHV was washed in heparinized blood of the recipient animal and was loaded into the delivery device by crimping the outer diameter from 25 mm down to 8 mm.
Histology & Scanning Electron Microscopy
Tissue samples of the explanted TEHV were analyzed qualitatively via immunohistochemistry / histology using Hematoxylin & Eosin staining and Masson-Trichrome staining. Representative tissue samples of TEHV were analyzed using Scanning Electron Microscopy and were fixed using 2% glutaralaldehyde. After preparation, samples were sputter-coated with platin and investigated with a Zeiss Supra 50 VP Microscope (Carl Zeiss Imaging, Germany).
Quantitative Explant Tissue Analysis
Explanted TEHV were lyophilized and analyzed by biochemical assays for total DNA and GAG content. For measuring the DNA amount, the Hoechst dye method was used [4] . The GAG content was determined using a modified version of the protocol described by Farndale et al. [5] and a standard curve prepared from chondroitin sulphate from shark cartilage (Sigma Chemical Co., St. Louis, USA).
Supplementary Figures
Supplementary Figure 1: Fabrication of stented bone marrow mononuclear cell based tissue engineered heart valves (TEHV)
Trileaflet heart valve scaffolds were fabricated from non-woven polyglycolic-acid meshes (PGA), coated with 1.75% poly-4-hydroxybutyrate (P4HB) and the scaffolds were integrated into radially self-expandable nitinol stents attaching the scaffold matrix to the inner surface of the nitinol stent wires (A). Thereafter, bone marrow was aspirated from the sternum of adult sheep into a heparinized syringe using a 12 Gauge threpine needle (B and C) and bone marrow mononuclear cells (BMMCs) were obtained by centrifuging the samples on a histopaque density gradient. Fibrin was used as a cell carrier to seed BMMCs onto the stented heart valve scaffolds (D).
Supplementary Figure 2:
Scanning electron microscopy of acute tissue engineered heart valve (TEHV) explants
Acute TEHV explants revealed a surface with fibrin reaction characterized by thrombocyte aggregation as well as leucocyte attachment (A and B).
Supplementary Figure 3: Extracellular Matrix Analysis of tissue engineered heart valve (TEHV) explants
Extracellular matrix analysis displayed continuously increasing DNA (A) as well as GAG (B)
values in the TEHV with increasing time in vivo achieving approximately 50% of native leaflets after two weeks.
Supplementary Trailers
Supplementary Trailer 1
Fluoroscopy guided transapical delivery of stem cell based tissue engineered heart valves (TEHV) into the orthotopic aortic valve position.
